The @LumiraDx Platform: 1 instrument with 1 simple workflow and 1 intuitive touchscreen. Specifically designed to be easy to use, with minimal training, equipment and maintenance required. Find out more at https://t.co/h1d2228XAM #POCT#LMDX#Diagnostics
@florian30260@Chronopost@ChronopostSAV chez nous c'est le jeté en hauteur la spécialité .... méme sous la pluie ..... au prire colis détruit mais belle performance
@Chronopost@FestivalDeNimes@nimes A quoi ca sert de faire de la la livraison green alors que vos colis sont jetés systématiquement au dessus d'un portail de 3 m, y compris quand il pleut ...... du grand n'importe quoi : ville senlisse 78 , N° MK993374227FR livraison aujourd'hui 22/06 .....
@Chronopost A quoi ca sert de faire de la qualité en entrepôts alors que vos colis sont jetés systématiquement au dessus d'un portail de 3 m, y compris quand il pleut ...... du grand n'importe quoi : ville senlisse 78 , N° MK993374227FR livraison aujourd'hui 22/06 .....
LumiraDx Platform really can go almost anywhere – next week you’ll find us testing on a bus! Where we'll be offering our direct fingerstick NT-proBNP Test at the FREE heart failure screening event #starttalkingaboutyourheart@AwcModality@pumpinghearts@ActAsOneBDC @MedtronicUK
The @LumiraDx assay can quickly verify potential infection for patients suspected of #influenza and/or #COVID19, helping to identify and differentiate the underlying cause of respiratory illness and inform treatment decisions at the #POC.
#LMDX
https://t.co/NfGyt1k1gG
Nouvelle génération de test antigénique « microfluidique » déployé en Afrique par la fondation de Bill Gates …. Nouveaux outils réduisant les faux négatifs de 10 à 30% @ivanrioufol@PascalPraud
Where you live shouldn’t determine whether or not you have access to a Covid-19 vaccine, health supplies, or a diagnostic test: https://t.co/DbwClIBRox
Where you live shouldn’t determine whether or not you have access to a Covid-19 vaccine, health supplies, or a diagnostic test: https://t.co/DbwClIBRox
LumiraDx Chief Product Officer, Pooja Pathak was recently interviewed by @MDDIonline on the increased demand across the US for #COVID19 testing and how LumiraDx is responding.
#LMDX#POCT#Diagnostics
Today we announced we have received emergency use approval from India’s Central Drugs Standard Control Organisation for our SARS-CoV-2 Antigen test for use in India.
#covid19testing $LMDX #india#sarscov2#POCT
https://t.co/zYJCuCeHpc
A quand la reconnaissance et l’utilisation de test antigenique de dernière génération comme en Europe et aux États Unis pour éviter les 10-30%de faux négatifs avec les tests bandelette . Efficace même chez les asymptomatiques. @PascalPraud@ivanrioufol
Intended Use for our #FDA#EUA Authorized High Sensitivity #COVID19 Antigen Test is Expanded to Include Testing of #Asymptomatic Individuals $LMDX https://t.co/X02NdXRv90
Intended Use for our #FDA#EUA Authorized High Sensitivity #COVID19 Antigen Test is Expanded to Include Testing of #Asymptomatic Individuals $LMDX https://t.co/X02NdXRv90
LumiraDx’s Chief Product Officer, Pooja Pathak writes about the impact of onsite COVID-19 testing and other point of care diagnostics in the workplace.
#LumiraDx#workplacehealth#covid19testing
https://t.co/dKR5bP4Pdu